Independent register of U.S. FDA drug recalls · updated Oct 10, 2026
RxRecalls Get alerts

Is Fluorescein recalled?

Yes — there is an active recall. 8 ongoing FDA recalls mention Fluorescein (18 total). Check the affected lots below.

Most common reason: Sterility / contamination (9 of these recalls)

Recalls are matched by product description. A recall usually affects specific lots, not every package of Fluorescein. “Active” means an FDA recall is still ongoing; “closed” means it was terminated or completed. Checked against openFDA on Oct 10, 2026.

Fluorescein recalls on record

none so far in 2026; 18 on record, newest first
Class II · Moderate risk

Ful-Glo

Failed Impurities/Degradation Specifications: The Active Pharmaceutical Ingredient (API) used in the product is not being manufactured to the current USP monograph in regard to Unspecified Impurities.

Ongoing Impurity / degradation Nomax Inc NDC 17478-404-01 D-0465-2024
Class II · Moderate risk

Ful-Glo

Failed Impurities/Degradation Specifications: The Active Pharmaceutical Ingredient (API) used in the product is not being manufactured to the current USP monograph in regard to Unspecified Impurities.

Ongoing Impurity / degradation Nomax Inc NDC 17478-403-03 D-0464-2024
Class II · Moderate risk

GloStrips

Failed Impurities/Degradation Specifications: The Active Pharmaceutical Ingredient (API) used in the product is not being manufactured to the current USP monograph in regard to Unspecified Impurities.

Ongoing Impurity / degradation Nomax Inc NDC 51801-009-40 D-0463-2024
Class II · Moderate risk

GloStrips

Failed Impurities/Degradation Specifications: The Active Pharmaceutical Ingredient (API) used in the product is not being manufactured to the current USP monograph in regard to Unspecified Impurities.

Ongoing Impurity / degradation Nomax Inc NDC 51801-003-40 D-0462-2024
Class III · Low risk

Fluorescein Sodium Ophthalmic Strips USP

Failed Content Uniformity Specifications: The product may not meet finished product release specifications, including the uniformity of dosage due to a packaging degradation related to the adhesive component of the paper pouch that can impact the level of fluorescein present in the strips.

Terminated Wrong potency / content Nomax Inc NDC 17478-404-01 D-0963-2015
Class III · Low risk

Fluorescein Sodium Ophthalmic Strips USP

Failed Content Uniformity Specifications: The product may not meet finished product release specifications, including the uniformity of dosage due to a packaging degradation related to the adhesive component of the paper pouch that can impact the level of fluorescein present in the strips.

Terminated Wrong potency / content Nomax Inc NDC 51801-003-01 D-0961-2015
Class II · Moderate risk

Fluorescein Sodium active pharmaceutical ingredient packaged in…

Penicillin Cross Contamination: All lots of all products repackaged and distributed between 01/05/12 and 02/12/15 are being recalled because they were repackaged in a facility with penicillin products without adequate separation which could introduce the potential for cross contamination with penicillin.

Terminated Cross-contamination Attix Pharmaceuticals D-682-2015
Class II · Moderate risk

Fluorescein/Indocyanine

Lack of Assurance of Sterility: Franck's Lab Inc. initiated a recall of all Sterile Human Drugs distributed between 11/21/2011 and 05/21/2012 because FDA environmental sampling revealed the presence of microorganisms and fungal growth in the clean room where sterile products were prepared.

Terminated Sterility / contamination Franck's Lab Inc., d.b.a. Franck's Compounding Lab D-1519-2012